|Benchmarking and Quality Best Practices
Best Practices, LLC has conducted extensive research in the field of Benchmarking and Quality. Browse through and sample our published Benchmarking and Quality research in the topics below:
| || |
|Medical Affairs’ Role in Health Economics & Outcomes Research within Oncology|
Non-members: Click here to review a complimentary excerpt from "Medical Affairs' Role in Health Economics & Outcomes Research within Oncology"
As payers and consumers increasingly seek patient outcomes data and clinical evidence supporting the product, biopharmaceutical companies are turning to their medical affairs function to effectively streamline the dissemination of medical information.
Development of strong health outcomes (HO) capabilities within Medical Affairs (MA) organizations requires an increase in MA’s involvement with HO groups, development of field-based HO capabilities, customization of HO data by stakeholders, and building real world data capabilities to generate and utilize HO information.
Best Practices, LLC conducted this study to help companies focused on oncology therapies find better ways to develop successful Health Outcomes groups. This research delivers current data and best practices from Medical Affairs leaders with an oncology focus at top biopharmaceutical companies.
• Longevity of HO Groups
• HO Leadership
• HO Reporting Structure
• HO Group Staffing
• MA’s Role in HO Activities
• MA’s Role in Collecting HO Data
• Utilization of HO Data
• Impact of HO Data on Decisions
• Length of Health Outcomes (HO) Programs
• HO Leadership Within Benchmark Class
• Reporting Structure: To whom does the Health Outcomes group(s) report?
• Number of Field and Office Based HO’s FTEs
• Percentage of Field-Based HO FTEs
• Core Field-Based HO Responsibilities
• Medical Affair’s Involvement in HO Activities
• Medical Affair’s Role in Collecting HO Data
• Utilizing the Health Outcomes Data To Inform Patients
• Utilizing the Health Outcomes Data To Inform Payers
• Utilizing the Health Outcomes Data To Inform Providers
• Effect of HO Data on Critical Decisions
SAMPLE KEY FINDINGS
• Longevity of HO Groups: HO programs are common, but they represent a young initiative for many of the benchmark class; sixty percent of companies have had it in place for less than three years.
• Reporting Structure: 60% of companies’ HO groups report to Medical Affairs. A majority of the interviewed executives think that HO groups must report to a science and research oriented department such as clinical or medical affairs. Between these two, medical affairs provides better opportunities for needs assessment, communicating HO data insights, and interacting with key decision makers.
Best Practices, LLC engaged 10 executives from leading life sciences companies. The analysis is focused on companies with oncology therapies.
Best Practices and the Role of Medical Affairs in Oncology Launch Excellence
Non-members: Click here to review a complimentary excerpt from "Best Practices and the Role of Medical Affairs in Oncology Launch Excellence”
Regulatory reforms in the healthcare industry have transformed the role of the Medical Affairs function. It has evolved beyond its traditional support role into a more prominent oncology launch role that extends from the pre-launch phase to well beyond market entry.
As an interface between biopharmaceutical companies and external stakeholders, the Medical Affairs group plays a critical role in the successful launch of oncology products. Best Practices, LLC conducted this study to provide benchmarks on how Medical Affairs' leaders with oncology companies approach launch activities around thought leaders, MSLs, and launch investment. The study provides best practices and winning strategies in oncology launch excellence from Medical Affairs leaders at leading biopharmaceutical companies.
· Medical Affairs' Role in Launch Activities
· Thought Leader Tiering
· Thought Leader Targeting and MSL Coverage
· Launch Investment
· Medical Affairs Investment Allocation
SAMPLE KEY METRICS
· Timing of Strategies Used for Thought Leader (TL) Tiering
· Number of Thought Leaders Targeted During Pre-Launch and Post-Launch
· Number of Medical Science Liaisons (MSLs) Employed During Pre-Launch and Post-Launch
· Number of TLs Targeted Per MSLs Employed During Pre-Launch and Post-Launch
· Total Launch Investment - Pre-Launch and Post-Launch
· Total Medical Affairs Launch Investment - Pre-Launch and Post-Launch
· Number of Medical Affairs Launch FTEs per Product - Pre-Launch and Post-Launch
· Percentage of Total Medical Affairs Launch Investment Allocated to Different Medical Affairs Activities
SAMPLE KEY FINDING
· Medical Affairs’ Role in Launch Activities: Medical Affairs is heavily involved in four launch activities within participating organizations: Scientific Publication, Continuing Medical Education, Real World Data Generation & Analysis, MSL activities.
Ø Medical Affairs leads TL Activities and plays a key role between companies and decision makers during launch process. This requires companies to create strong MSL teams, acquire the right talent and provide effective training.
Ø Medical Affairs also plays a critical role in internal education and guiding commercial strategies regarding products. This provides Medical Affairs leaders with the opportunity to convey the needs of key decision makers, thus companies to improve their products.
Best Practices, LLC engaged 11 executives from leading life sciences companies. The study analyzes companies that focus on oncology therapies.